02:06 , May 11, 2018 |  BC Innovations  |  Finance

Amplifying oligos

The last five years have seen a steady stream of preclinical deals for antisense, siRNA and mRNA therapies that suggests pharmas are taking the modalities seriously as alternatives to traditional small molecules and antibodies. But...
19:49 , Aug 18, 2017 |  BC Week In Review  |  Clinical News

Ophthotech's Fovista misses in third Phase III for AMD

Ophthotech Corp. (NASDAQ:OPHT) reported data from the double-blind, sham-controlled, international Phase III OPH1004 trial in about 640 patients with wet age-related macular degeneration (AMD) showing that intravitreal injections of 1.5 mg Fovista pegpleranib plus Eylea...
20:25 , Dec 16, 2016 |  BC Week In Review  |  Clinical News

Fovista: Ph III OPH1002 data

The double-blind, sham-controlled, international Phase III OPH1002 trial in 619 patients with wet AMD showed that intravitreal injections of 1.5 mg Fovista plus 0.5 mg Lucentis ranibizumab missed the primary endpoint of improving the mean...
20:24 , Dec 16, 2016 |  BC Week In Review  |  Clinical News

Fovista: Ph III OPH1003 data

The double-blind, sham-controlled, international Phase III OPH1003 trial in 626 patients with wet AMD showed that intravitreal injections of 1.5 mg Fovista plus 0.5 mg Lucentis ranibizumab missed the primary endpoint of improving the mean...
01:15 , Dec 13, 2016 |  BC Extra  |  Clinical News

Ophthotech craters after Phase III AMD failure

Ophthotech Corp. (NASDAQ:OPHT) lost $33.48 (86%) to $5.29 on Monday after it said Fovista pegpleranib missed the primary endpoints in the Phase III OPH1002 and OPH1003 trials to treat wet age-related macular degeneration. In both studies,...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
07:00 , Sep 30, 2016 |  BC Extra  |  Clinical News

Regeneron combo fails to top Eylea alone in AMD study

Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) said intravitreal injections of REGN2176-3 missed the primary endpoint in the ongoing Phase II CAPELLA study to treat wet age-related macular degeneration. The therapy, which combines the company's ophthalmic drug...
07:00 , Jun 27, 2016 |  BC Week In Review  |  Clinical News

Fovista pegpleranib: Completed Phase III enrollment

Ophthotech completed enrollment of about 622 patients in the last of 3 sham-controlled, double-blind, international Phase III trials evaluating intravitreal injections of 1.5 mg Fovista. The trial is comparing Fovista and intravitreal injections of 2...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Ophthotech, Novartis, Roche deal

Roche’s Genentech Inc. unit exercised its option to share with Novartis ex-U.S. rights to Fovista pegpleranib from Ophthotech. Novartis has ex-U.S rights to develop and commercialize the wet age-related macular degeneration (AMD) candidate...
01:45 , Nov 19, 2015 |  BC Extra  |  Company News

Genentech, Novartis to share ex-U.S. Fovista rights

The Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) exercised its option to share ex-U.S. rights to wet age-related macular degeneration (AMD) candidate Fovista pegpleranib with Novartis AG (NYSE:NVS; SIX:NOVN). The partners already market Lucentis ranibizumab...